Effects of opioids, cannabinoids, and vanilloids on body temperature

Frontiers in Bioscience - Scholar

Volumn 3 S, Issue 3, 2011, Pages 822-845

  Rawls, Scott M ^a,b   Benamar, Khalid ^b  

^a Temple University Health Sciences Center   (United States)

^b TEMPLE UNIVERSITY   (United States)

Author keywords

Ananandamide; Body Temperature; Cannabinoid; Opioid; Sigma; Thermoregulation; TRP81; TRPM8; TRPV1

Indexed keywords

4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; AGMATINE; ARGIPRESSIN; BETA 2 ADRENERGIC RECEPTOR; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CEFTRIAXONE; DELTA OPIATE RECEPTOR; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; FLUOXETINE; GLYCERYL TRINITRATE; IMIDAZOLINE; KAPPA OPIATE RECEPTOR; LOPERAMIDE; MORPHINE; MU OPIATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NALOXONAZINE; NALTREXONE; NALTRINDOLE; NICOTINIC RECEPTOR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OPIATE RECEPTOR; SEROTONIN 3 RECEPTOR; TRANSIENT RECEPTOR POTENTIAL CHANNEL M8; VANILLOID RECEPTOR; BENZALDEHYDE DERIVATIVE; CANNABINOID; NARCOTIC ANALGESIC AGENT; SIGMA OPIATE RECEPTOR; VANILLIN;

ANTERIOR HYPOTHALAMUS; ARTICLE; BASAL BODY TEMPERATURE; BINDING AFFINITY; BINDING SITE; BLOOD BRAIN BARRIER; BODY TEMPERATURE; BODY TEMPERATURE DISORDER; BROWN ADIPOSE TISSUE; CELL MEMBRANE; CHEMICAL STRUCTURE; CHLORIDE CONDUCTANCE; COLD; ENANTIOSELECTIVITY; FRONTAL CORTEX; GABAERGIC TRANSMISSION; GENE DELETION; HEAT LOSS; HUMAN; HYDROLYSIS; HYPERPOLARIZATION; HYPERTHERMIA; HYPOTHERMIA; IMMOBILIZATION STRESS; IMMUNOREACTIVITY; INDUCED HYPOTHERMIA; LATERAL BRAIN VENTRICLE; LOCOMOTION; MAST CELL; MEMBRANE STEADY POTENTIAL; NONHUMAN; PHENOTYPE; PROTEIN PHOSPHORYLATION; RECEPTOR DENSITY; SECOND MESSENGER; THERMOGENESIS; THERMOREGULATION; VASCULAR SMOOTH MUSCLE; ANIMAL; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; PHYSIOLOGY; REVIEW;

ANALGESICS, OPIOID; ANIMALS; BENZALDEHYDES; BODY TEMPERATURE; BODY TEMPERATURE REGULATION; CANNABINOIDS; HUMANS; HYPOTHERMIA; RECEPTORS, CANNABINOID; RECEPTORS, OPIOID; RECEPTORS, SIGMA;

EID: 80053126457     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/s190     Document Type: Article

References (289)

1. EB Geller, C Hawk, RJ, Tallarida, MW Adler: Postulated thermoregulatory roles for different opiate receptors in rats. Life Sci 31, 2241-2244 (1982)
2. EB Geller, C Hawk, SH Keinath, RJ Tallarida, MW Adler: Subclasses of opioids based on body temperature change in rats: Acute subcutaneous administration. J Pharmacol Exp Ther 225, 391-8 (1983)
3. K Benemar, L Xin, EB Geller, MW Adler: Role of the nitric oxide pathway in kappa-opioid-induced hypothermia in rats: J Pharmacol Exp Ther 303, 375-8 (2002)
4. RL Spencer, VJ Hruby, TF Burks: Body temperature response profiles for selective mu, delta and kappa opioid agonists in restrained and unrestrained rats. J Pharmacol Exp Ther 246,92-101 (1988)
5. CM Handler, EB Geller, MW Adler: Effect of mu-, kappa-, and delta-selective opioid agonists on thermoregulation in the rat. Pharmacol Biochem Behav 43, 1209-16 (1992)
6. MW Adler, EB Geller: Physiological functions of opioids: Temperature regulation. Opoids II. Herz, A., Akil, H. and Simon, E.J., Editors, 1993. Handbook of Experimental Pharmacology Vol. 104/II, Springer-Verlag, Berlin Heidelberg (1993)
7. MV Adler: Multiple opiate receptors and their different ligand profiles. Ann N Y Acad Sci 398, 340-51 (1982)
8. EB Geller, CH Rowan, MW Adler: Body temperature effects of opioids in rats: Intracerebroventricular administration. Pharmacol Biochem Behav 24, 1761-65 (1986)
9. MW Adler, EB Geller, CE Rosow, J Cochin: The opioid system and temperature regulation: Annu Rev Pharmacol Toxicol 28, 429-49 (1988)
10. CM Handler, TC Piliero, EB Geller, MW Adler: Effect of ambient temperature on the ability of mu-, kappa-And delta-selective opioid agonists to modulate thermoregulatory mechanisms in the rat. J Pharmacol Exp Ther 268, 847-55 (1994)
11. XH Chen, EB Geller, JK De Riel, LY Liu-Chen, MW Adler: Antisense oligodeoxynucleotides against mu-or kappa-opioid receptors block agonist-induced body temperature changes in rats. Brain Res 668, 237-41 (1995)
12. XH Chen, EB Geller, JK De Riel, LY liu-Chen, MW Adler: Antisense confirmation of mu-And kappa-opioid receptor mediation of morphine's effects on body temperature in rats. Drug Alcohol Depend 43, 119-24 (1996)
13. X Chen, DB McClatchy, EB Geller, RJ Tallarida, MW Adler: The dynamic relationship between mu and kappa opioid receptors in body temperature regulation. Life Sci 78, 329-33 (2005)
14. Y Wang, Y Chen, W Xu, DY Lee, Z Ma, SM Rawls, A Cowan, LY Liu-Chen: 2-Methoxymethyl-salvinorin B is a potent kappa opioid receptor agonist with longer lasting action in vivo than salvinorin. A J Pharmacol Exp Ther 324,1073-83 (2008)
15. KV Nemmani, S Gullapalli, P Ramarao: Potentiation of kappa-opioid receptor agonist-induced analgesia and hypothermia by fluoxetine. Pharmacol Biochem Behav 69, 189-93 (2001)
16. L Xin, EB Geller, MW Adler: Body temperature and analgesic effects of selective mu and kappa opioid receptor agonists microdialyzed into rat brain. J Pharmacol Exp Ther 281, 499-507 (1997)
17. SM Rawls, RJ Tallarida, W Robinson, M Amin: The beta-lactam antibiotic, ceftriaxone, attenuates morphine evoked hyperthermia in rats. Br J Pharmacol 151, 1095-102 (2007)
18. VK Shukla, H Turndorf, M Bansinath: Pertussis and cholera toxins modulate kappa-opioid receptor agonistsinduced hypothermia and gut inhibition. Eur J Pharmacol 16, 292-9 (1995)
19. CM Handler, H Turndorf, M Bansinath: Interaction between opioid agonists and neurotensin on thermoregulation in the rat. I. Body temperature. J Pharmacol Exp Ther 274, 284-92 (1995)
20. S Gullapalli, KV Nemmani, P Ramarao: Role of Ca2+ channels on the hypothermic response produced by activation of kappa-opioid receptors. Pharmacol Biochem Behav 72, 93-9 (2002)
21. S Gullapalli, P Ramarao: L-Type Ca2+ channel modulation by dihydropyridines potentiates kappa-opioid receptor agonist induced acute analgesia and inhibits development of tolerance in rats. Neuropharmacology 42, 467-75 (2002)
22. S. Gullapalli, P Ramarao: P. Role of L-Type Ca2+ channels in pertussis toxin induced antagonism of U50,488H analgesia and hypothermia. Brain Res 946, 191-7 (2002)
23. P Salmi, J Kela, U Arvidsson, C Wahlestedt: Functional interactions between delta-And mu-opioid receptors in rat thermoregulation. Eur J Pharmacol 458, 101-6 (2003)
24. AC Costa, MR Stasko, M Stoffel, JJ Scott-McKean: G-protein-Gated potassium(GIRK) channels containing the GIRK2 subunit are control hubs for pharmacologically induced hypothermic responses. J Neurosci 25, 7801-4 (2005)
25. MW Adler, EB Geller: Fypothermia and poikilothermia induced by a kappa-Agonist opioid and a neuroleptic. Eur J Pharmacol 140, 233-37 (1987)
26. DS Bredt, SH Snyder: Nitric oxide, a novel neuronal messenger: Neuron 8, 3-11 (1992)
27. CD Breder, CB Saper: Expression of inducible cyclooxygenase mRNA in the mouse brain after systemic administration of bacterial lipopolysaccharide. Brain Res 713, 64-9 (1996)
28. MO Lopez-Figueroa, HE Day, H Akil, SJ Watson: Nitric oxide in the stress axis. Histol Histopathol.13, 1243-52 (1998)
29. S Moncada, RMJ Palmer, EA Higgs: Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol Rev 43, 109-42 (1991)
30. CJ Lowenstein, CS Glatt, DS Bredt, SH Snyder: Cloned and expressed macrophage nitric oxide synthase contrasts with brain enzyme. Proc Natl Acad Sci U. S. A. 89, 6711-15 (1992)
31. AV Gourine: Pharmacological evidence that nitric oxide can act as an endogenous antipyretic factor in endotoxin-induced fever in rabbits. Gen Pharmacol 26, 835-41 (1995)
32. LG Branco, EC Carnio, RC Barros: Role of the nitric oxide pathway in hypoxia-induced hypothermia of rats. Am J Physiol 273, 967-71 (1997)
33. AA Steiner, EC Carnio, J Antunes-Rodrigues, LG Branco: Role of nitric oxide in systemic vasopressin-induced hypothermia. Am J Physiol 275, 937-41 (1998)
34. MC Almedia, LGS Branco: Role of nitric oxide in insulin-induced hypothermia in rats. Brain Res Bull 54 , 49-53 (2001)
35. JH Lin, MT Lin: Nitric oxide synthase-Cyclo-oxygenase pathway in organum vasculosum laminae terminalis: Possible role in pyrogenic fever in rabbits. Br J Pharmacol 118, 179-185 (1996)
36. TE Scammell, JK Elmquist, CB Saper: Inhibition of nitric oxide synthase produces hypothermia and depresses lipopolysaccharide fever. Am J Physiol 271, R 333-8 (1996)
37. J Roth, B Störr, K Voigt, E Zeisberger: Inhibition of nitric oxide synthase results in a suppression of interleukin-1-induced fever in rats. Life Sci 62, 333-8 (1998)
38. K Benamar, L Xin, EB Geller, MW Adler: Blockade of lipopolysaccharide- induced fever by a ?-opioid receptorselective antagonist in rats. Eur J Pharmacol 401, 161-5 (2000)
39. WF Taylor, VS Bishop: A role for nitric oxide in active thermoregulatory vasodilation. Am J Physiol 264, 1355-9 (1993)
40. T. Nagashima, H Ohinata, A Kuroshima: Involvement of nitric oxide in noradrenaline-induced increase in blood-Flow through brown adipose tissue. Life Sci 54, 17-25 (1994)
41. M. Yamada, A Inanobe, Y Kurachi: G protein regulation of potassium ion channels. Pharmacol Rev 50, 732-60 (1998)
42. K Wickman, C Karschin, A Karschin, MR Picciotto, De Clapham: Brain localization and behavioral impact of the Gprotein-Gated K+ channel subunit GIRK4. J Neurosci 20, 5608-15 (2000)
43. HC Jackson, DJ Nutt: Inhibition of baclofen-induced hypothermia in mice by the novel GABAB antagonist CGP 35348. Neuropharmacology. 30, 353-8 (1991)
44. E Meller, M Chalfin, K Bohmaker: Serotonin 5-HT1A receptor-mediated hypothermia in mice: Absence of spare receptors and rapid induction of tolerance. Pharmacol Biochem Behav 43,405-11 (1992)
45. R Anderson, MJ Sheehan, P Strong: Characterization of the adenosine receptors mediating hypothermia in the conscious mouse. Br J Pharmacol 113, 1386-90 (1994)
46. JE Malberg, LS Seiden: Administration of fenfluramine at different ambient temperatures produces different core temperature and 5-HT neurotoxicity profiles. Brain Res 765, 101-107 (1997)
47. A Eltayb, S Lindblom, S Oerther, S Ahlenius: Additive hypothermic effects of the 5-HT1A receptor agonist 8-OHDPAT and the dopamine D2/3 receptor agonist 7-OHDPAT in the rat. Acta Physiol Scand 172, 205-9 (2001)
48. AK Baker, TF Meert: Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice. J Pharmacol Exp Ther 302, 1253-64 (2002)
49. PF Von Voigtlander, RA Lewis: U-50,488, a selective kappa opioid agonist: Comparison to other reputed kappa agonists. Prog Neuropsychopharmacol Biol Psychiatry 6, 467-70 (1982)
50. MV Milanes, ML Gonzalvez, T Fuente, ML Vargas: Pituitary-Adrenocortical response to acute and chronic administration of U-50,488H in the rat. Neuropeptides 20, 95-102 (1991)
51. SM Rawls, W Robinson, S Patel, A Baron: Beta-lactam antibiotic prevents tolerance to the hypothermic effect of a kappa opioid receptor agonist. Neuropharmacology 55, 865-70 (2008)
52. KA Trujillo, H Akil: Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 251, 85-7 (1991)
53. YA Kolesnikov, J Ferkany, GW Pasternak: Blockade of mu and kappa 1 opioid analgesic tolerance by NPC17742, a novel NMDA antagonist. Life Sci 53, 1489-94 (1993)
54. GK Aghajanian, JH Kogan, B Moghaddam: Opiate withdrawal increases glutamate and aspartate efflux in the locus coeruleus: An in vivo microdialysis study. Brain Res 636, 126-30 (1994)
55. P Marek, S Ben-Eliyahu, M Gold, JC Liebeskind: Excitatory amino acid antagonists (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rat. Brain Res 547, 77-81 (1991)
56. GW Pasternak, YA Kolesnikov, AM Babey: Perspectives on the N-methyl-D-Aspartate/nitric oxide cascade and opioid tolerance. Neuropsychopharmacology 13, 309-13 (1995)
57. P Popik, P Skolnick: The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence. Pharmacol Biochem Behav 53, 791-7 (1996)
58. HN Bhargava, SN Thorat: Effect of dizocilpine (MK-801) on analgesia and tolerance induced by U-50,488H, a kappa-opioid receptor agonist, in the mouse: Brain Res 649, 111-6 (1998)
59. HN Bhargava: Non-Competitive antagonism of Nmethyl-D-Aspartate receptor inhibits tolerance to the analgesic action of U-50,488H, a kappa-opiate receptor agonist in the rat. Gen Pharmacol 26,1055-60 (1995)
60. K Lutfy, P Doan, M Nguyen, E Weber: Effects of ACEA-1328, a NMDA receptor/glycine site antagonist, on U50,488H-induced antinociception and tolerance. Eur J Pharmacol 384, 1-5 (1999)
61. K Elliott, N Minami, YA Kolesnikov, GW Pasternak, CE Inturrisi: The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NGnitro-L-Arginine, attenuate analgesic tolerance to the muopioid morphine but not to kappa opioids. Pain 56, 69-75 (1994)
62. HN Bhargava, SN Thorat: Differential effects of LY235959, a competitive antagonist of the NMDA receptor on kappa-opioid receptor agonist induced responses in mice and rats. Brain Res 747, 246-51 (1997)
63. SM Rawls, JA Schroeder, Z Ding, T Rodriguez, N Zaveri: NOP receptor antagonist, JTC-801,blocks cannabinoid-evoked hypothermia in rats. Neuropeptides 41, 239-47 (2007b)
64. SM Rawls, DA Baron, JK Kim: ?-lactam antibiotic inhibits development of morphine physical dependence in rats. Behav Pharmacol 41, 239-47 (2007b)
65. JD Rothstein, S Patel, MR Regan, C Haenggeli, YH Huang, De Bergles, L Jin, M Dykes Hoberg, S Vidensky, DS Chung, SV Toan, LI Bruijn, ZZ Su, P Gupta, PB Fisher: Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433, 73-7(2005)
66. BR Miller,JL Dorner, M Shou, Y Sari, SJ Barton, DR Sengelaub, RT Kennedy, GV Rebec: Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse. Neuroscience 153, 329-37 (2008)
67. Y Sari, KD Smith, PK Ali, GV Rebec: Upregulation of GLT1 attenuates cue-induced reinstatement of cocaineseeking behavior in rats. J Neurosci 29, 9239-43.
68. LA Knackstedt, RI Melendez, PW Kalivas: Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine seeking. Biol Psychiatry in press 2009.
69. J Lipski, CK Wan, JZ Bai, R Pi, D Li: Donnelly, D. Neuroprotective potential of ceftriaxone in in vitro models of stroke. Neuroscience 146, 617-29 (2007)
70. K Chu, ST Lee, Di Sinn, SY Ko, EH Kim, JM Kim, SJ Kim, DK Park, KH Jung, EC Song, SK Lee, M Kim, JK glutamate transporter-1 (EAAT2) upregulation. Stroke 38, 177-82 (2007)
71. N Melzer, SG Meuth, D Torres-Salazar, S Bittner, AL Zozulya, C Weidenfeller, A Kotsiari, M Stangel, C Fahlke, H Wiendl: A ?-lactam antibiotic dampens excitotoxic inflammatory CNS damage in a mouse model of multiple sclerosis. PLoS ON 3, e3149 (2008)
72. M Broccardo, G Improta, A Tabacco: Central effect of SNC 80, a selective and systemically active delta-opioid receptor agonist, on gastrointestinal propulsion in the mouse. Eur J Pharmacol 342, 247-51 (1998)
73. LA Pohorecky, A Skiandos, X Zhang, KC Rice, D Benjamin: Effect of chronic social stress on delta-opioid receptor function in the rat. J Pharmacol Exp Ther 290, 196-206 (1999)
74. SM Rawls, JM Hewson, S Inan, A Cowan: Brain delta2 opioid receptors mediate SNC-80-evoked hypothermia in rats. Brain Res 1049, 61-9 (2005)
75. SM Rawls, A Cowan: Modulation of delta opioidevoked hypothermia in rats by WAY 100635 and fluoxetine. Neurosci Lett 398, 319-24 (2006)
76. EJ Bilsky, SN Calderon, T Wang, RN Bernstein, P Davis, VJ Hruby, RW McNutt, RB Rothman, KC Rice, F Porreca: SNC 80, a selective, nonpeptidic, and systemically active opioid delta agonist. J Pharmacol Exp Ther 273, 359-366 (1995)
77. DC Broom, EM Jutkiewicz, JE Folk, Jr. Traynor, KC Rice, JH Woods: Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats. Neuropyschopharmacology 26, 744-55 (2002)
78. SN Calderon, RB Rothman, F Porreca, JL Flippen-Anderson, RW McNutt, H Xu, LE Smith, EJ Bilsky, P Davis, KC Rice: Probes for narcotic receptor mediated phenomena. Synthesis of (+)-4-[(alpha R)-Alpha-((2S,5R)-4-Allyl-2,5-Dimethyl-1- piperazinyl)-31 methoxybenzyl]-N,N-Diethylbenzamide (SNC 80): A highly selective, nonpeptide delta opioid receptor agonist. J Med Chem 7, 2125-28 (1994)
79. RM Quock, Y Hosohata, RJ Knapp, TH Burkey, K Hosohata, X Zhang , KC Rice, H Nagase, VJ Hruby, F Porreca, WR Roeske WR, HI Yamamura: Relative efficacies of delta-opioid receptor agonists at the cloned human delta-opioid receptor. Eur J Pharmacol 326, 101-104 (1997)
80. RJ Knapp, G Santoro, IA De Leon, KB Lee, SA Edsall, S Waite, E Malatynska, E Varga, SN Calderon, KC Rice, RB Rothman, F Porreca, WR Roeske, HI Yamamura: Structure-Activity relationships for SNC80 and related compounds at cloned human delta and mu opioid receptors. J Pharmacol Exp Ther 277, 1284-91 (1996)
81. GL Fraser, H Parenteau, TM Tu, J Ducharme, MN Perkins, PB Clarke: The effects of delta agonists on locomotor activity in habituated and non-Habituated rats. Life Sci 67, 913-22 (2006)
82. JA Boulant, PJ Morgane, J Pankesepp, etc.: Fypothalamic control of thermoregulation. Neurophysiological basis in Behavioral Studies of the Hypothalamus Dekker, New York. 1-82 (1980)
83. A Mansour, H Khachaturian, ME Lewis, H Akil, SJ Watson: Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain. J Neurosci 7, 2445-64 (1987)
84. A Mansour, CA Fox, S Burke, F Meng, RC Thompson, H Akil, SJ Watson: Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: An in situ hybridization study. J Comp Neurol 350, 412-438 (1994)
85. SM Rawls, Z Ding, AM Gray, A Cowan: Peripheral kappa-opioid agonist, ICI 204448, evokes hypothermia in cold-exposed rats. Pharmacology 74, 79-83 (2005)
86. K Benamar, SM Rawls, EB Geller, MW Adler: Intrahypothalamic injection of deltorphin-II alters body temperature in rats. Brain Res 1019, 22-7 (2004)
87. MC Wallenstein: Role of adrenal medulla in morphineinduced hyperthermia through central action. Br J Pharmacol 76, 565-8 (1982)
88. SM Rawls, C Allebach, A Cowan: Nitric oxide synthase mediates delta opioid receptor-induced hypothermia in rats. Eur J Pharmacol 536, 109-12 (2006)
89. R Gomez-Flores, KC Rice, X Zhang, RJ Weber: Increased tumor necrosis factor-Alpha and nitric oxide production by rat macrophages following in vitro stimulation and intravenous administration of the deltaopioid agonist SNC. Life Sci 68, 2675-84 (2001)
90. N Nozaki-Taguchi, T Yamamoto: Involvement of nitric oxide in peripheral antinociception mediated by kappa-And delta-opioid receptors. Anesth Analg 87,388-93 (1998)
91. G Picolo, Y Cury: Peripheral neuronal nitric oxide synthase activity mediates the antinociceptive effect of Crotalus durissus terrificus snake venom, a delta-And kappa-opioid receptor agonist. Life Sci 75, 559-73 (2004)
92. K Gyires: The role of endogenous nitric oxide in the gastroprotective action of morphine. Eur J Pharmacol 255, 33-7 (1994)
93. DJ Critchley, KJ Childs, VC Middlefell, CT Dourish: Inhibition of 8-OH-DPAT-induced elevation of plasma corticotrophin by the 5-HT1A receptor antagonist WAY100635. Eur J Pharmacol 264, 95-7 (1995)
94. A Fletcher, EA Forster, DJ Bill, G Brown, IA Cliffe, JE Hartley, De Jones, A McLenachan, KJ Stanhope, DJ Critchley, KJ Childs, VC Middlefell, L Lanfumey, R Corradetti, AM Laporte, H Gozlan, M Hamon, CT Dourish: Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist. Behav Brain Res 73, 337-53 (1996)
95. EA Forster, IA Cliffe, DJ Bil,l GM Dover, D Jones, Y Reilly, A Fletcher: A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635. Eur J Pharmacol 281, 81-8 (1995)
96. R Tao, SB Auerbach: Opoid receptor subtypes differentially modulate serotonin efflux in the rat central nervous system. J Pharmacol Exp Ther 203, 549-56 (2002)
97. KW Perry, RW Fuller: Effect of fluoxetine on serotonin and dopamine concentration in microdialysis fluid from rat striatum. Life Sci 50, 1683-90 (1992)
98. KW Perry, RW Fuller: Extracellular 5-Hydroxytryptamine concentration in rat hypothalamus after administration of fluoxetine plus L-5-Hydroxytryptophan. J Pharm Pharmacol 45, 759-61 (1993)
99. SM Rawls, MW Adler, JP Gaughan, A Baron, EB Geller, A Cowan: NMDA receptors modulate morphine-induced hyperthermia. Brain Res 984, 76-83 (2003)
100. BD Appelbaum, SG Holtzman: Stress-induced changes in the alalgesic and thermic effects of opioid peptides in the rat. Brain Res 377(2), 330-6 (1986)
101. EL Bradley, I Kissin, PT Brown, CA Robinson: Acute tolerance in morphine analgesia: Continuous infusion and single injection in rats. Anesthesiology 74(1), 166-71 (1991)
102. K Benamar, KM Yondorf, VT Barreto, EB Geller, MW Adler: Deletion of mu-opioid receptor in mice alters the development of acute neuroinflammation. J Pharmacol Exp Ther 323, 990-4 (2007a)
103. H Houshyar, MD Galigniana, WB Pratt, JH Woods: Differential responsivity of the hypothalamic-pituitary-Adrenal axis to glucocorticoid negative-Feedback and corticotropin releasing hormone in rats undergoing morphine withdrawal: Possible mechanisms involved in facilitated and attenuated stress responses. J Neuroendocrinol 13(10), 875-86 (2001)
104. GE Martin, AT Pryzbylik, NH Spector: Restraint alters the effects of morphine and heroin on core temperature in the rat. Pharmacol Biochem Behav 7, 463-469 (1977)
105. JN McDougal, PR Marques, TF Burks: Restraint alters the thermic response to morphine by postural interference. Pharmacol Biochem Behav 18, 495-9 (1983)
106. J Del Rio-Garcia, A Cremades: GABAergic mechanisms in morphine-induced hypothermia. Eur J Pharmacol 187, 495-500 (1990)
107. G Li, S Regunathan, DJ Reis: Agmatine is synthesized by a mitochondrial arginine decarboxylase in rat brain. Ann N Y Acad Sci 763, 325-9 (1995)
108. DJ Reis, S Regunathan: Is agmatine a novel neurotransmitter in brain? Trends Pharmacol Sci 21, 187-93 (2000)
109. HO Nguyen, CJ Goracke-Postle, LL Kaminski, AC Overland, AD Morgan, CA Fairbanks: Neuropharmacokinetic and dynamic studies of agmatine (decarboxylated arginine) Ann N Y Acad Sci 1009, 82-105 (2003)
110. M Sastre, S Regunathan, E Galea, DJ Reis: Agmatinase activity in rat brain: A metabolic pathway for the degradation of agmatine. J Neurochem 67, 1761-5 (1996)
111. JE Piletz, DN Chikkala, P Ernsberger: Comparison of the properties of agmatine and endogenous clonidine-Displacing substance at imidazoline and alpha-2 adrenergic receptors. J Pharmacol Exp Ther 272, 581-7 (1995)
112. XC Yang, DJ Reis: Agmatine selectively blocks the Nmethyl D-Aspartate subclass of glutamate receptor channels in rat hippocampal neurons. J Pharmacol Exp Ther 288, 544-9 (1999)
113. M Auguet, I Viossat, JG Marin, PE Chabrier: Selective inhibition of inducible nitric oxide synthase by agmatine. Jpn J Pharmacol 69(3), 285-7 (1995)
114. RH Loring: Agmatine acts as an antagonist of neuronal nicotinic receptors. Br J Pharmacol 99, 207-11 (1990)
115. RB Su, J Li, BY Qin: A biphasic opioid function modulator: Agmatine. Acta Pharmacol Sin 24, 631-6 (2003)
116. Y Kolesnikov, S Jain, GW Pasternak: Modulation of opioid analgesia by agmatine. Eur J Pharmacol 296, 17-22 (1996)
117. F Aricioglu, S Regunathan: Agmatine attenuates stressand lipopolysaccharide-induced fever in rats. Physiol Behav 85, 370-375 (2005)
118. G Olmos, N DeGregorio-Rocasolano, M Paz Regalado, T Gasull, M Assumpció Boronat, R Trullas, A Villarroel, J Lerma, JA García-Sevilla: Protection by imidazole(ine) drugs and agmatine of glutamate-induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor. Br J Pharmacol 127, 1317-26 (1999)
119. K Benamar, M McMenamin, EB Geller, YG Chung, JE Pintar, MW Adler: Unresponsiveness of mu-opioid receptor knockout mice to lipopolysaccharide- induced fever. Br J Pharmacol 144, 1029-31 (2005)
120. C Cunningham, DC Wilcockson, S Campion, K Lunnon, VH Perry: Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J Neurosci 25, 9275-84 (2005)
121. WR Martin, CG Eades, JA Thompson, RE Huppler, PE Gilbert: The effects of morphine-And nalorphine-like drugs in the nondependent and morphine-Dependent chronic spinal dog. J Pharmacol Exp Ther 197, 517-532 (1976)
122. SR Zukin, KT Brady, BL Slifer, RL Balster: Behavioral and biochemical stereoselectivity of sigma opiate/PCP receptors. Brain Res 294, 174-7 (1984)
123. R Quirion, WD Bowen, Y Itzhak, JL Junien, JM Musacchio, RB Rothman, TP Su, SW Tam, DP Taylor: A proposal for the classification of sigma binding sites. Trends Pharmacol Sci 13, 85-6 (1992)
124. Y Itzhak: Modulation of the PCP/NMDA receptor complex and sigma binding sites by psychostimulants. Neurotoxicol Teratol 16, 363-8 (1994)
125. WD Bowen, B De Costa, SB Hellewell, A Thurkauf, JM Walker, KC Rice: Characterization of [3H] (+)-pentazocine, a highly selective sigma ligand. Prog Clin Biol Res 328, 117-20 (1990)
126. SB Hellewell, WD Bowen: A sigma-like binding site in rat pheochromocytoma (PC12) cells: Decreased affinity for (+)-Benzomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain. Brain Res 527, 244-53 (1990)
127. M King, YX Pan, J Mei, A Chang, J Xu, GW Pasternak: Enhanced kappa-opioid receptor-mediated analgesia by antisense targeting the sigma1 receptor. Eur J Pharmacol 331, 5-6 (1997)
128. B Kest, JS Mogil, WF Sternberg, RN Pechnick, JC Liebeskind: Antinociception following 1,3,-Di-otolylguanidine, a selective sigma receptor ligand. Pharmacol Biochem Behav 50, 587-92 (1995)
129. M Bejanian, RN Pechnick, R George: Effects of acute and chronic administration of (+)-SKF 10,047 on body temperature in the rat: Cross-sensitization with phencyclidine. J Pharmacol Exp Ther 253, 1253-58 (1990)
130. M Bejanian, RN Pechnick, MP Bova, R George: Effects of subcutaneous and intracerebroventricular administration of the sigma receptor ligand 1,3-Di-otolylguanidine on body temperature in the rat: Interactions with BMY 14802 and rimcazole. J Pharmacol Exp Ther 258, 88-93 (1991)
131. S Hjorth, D Clark, A Carlsson: Lack of functional evidence for the involvement of sigma opiate receptors in the actions of the 3-PPP enantiomers on central dopaminergic systems: Discrepancies between in vitro and in vivo observations. Life Sci 37, 673-84 (1985)
132. WG Clark, GL Bernardini, SW Ponder: Central injection of a sigma opioid receptor agonist alters body temperature of cats. Brain Res Bull 7, 279-81 (1981)
133. E Weber, M Sonders, M Quarum, S McLean, S Pou, JF Keana: 1,3-Di(2-[5-3H]tolyl)guanidine: A selective ligand that labels sigma-Type receptors for psychotomimetic opiates and antipsychotic drugs. Proc Natl Acad Sci USA 83, 8784-8 (1986)
134. PC Contreras, ML Contreras, TL O?Donohue, CC Lair: Biochemical and behavioral effects of sigma and PCP ligands. Synapse 2, 240-3 (1998)
135. GF Steinfels, SW Tam, L Cook: Electrophysiological effects of selective sigma-receptor agonists, antagonists, and the selective phencyclidine receptor agonist MK-801 on midbrain dopamine neurons. Neuropsychopharmacology 2, 201-8 (1989)
136. PJ Brent: Similar behavioral effects of sigma agonists and PCP-like non-Competitive NMDA antagonists in guinea-pigs. Psychopharmacology 105, 421-7 (1991)
137. S Herling, EH Coale, DW Hein, G Winger, JH Woods: Similarity of the discriminative stimulus effects of ketamine, cyclazocine, and dextrorphan in the pigeon. Psychopharmacology 73, 286-91 (1981)
138. SG Holtzman: Phencyclidine-like discriminative effects of opioids in the rat. J Pharmacol Exp Ther 214, 614-619 (1980)
139. JH Woods, W Koek, E Weber: Behavioral similarities of di-Tolylguanidine (DTG), a selective ligand for haloperidolsensitive sigma binding sites, to phencyclidine (PCP), in rats, pigeons, rhesus monkeys. Fed Proc 46, 951 (1987)
140. SM Rawls, DA Baron, EB Geller, MW Adler: Sigma sites mediate DTG-evoked hypothermia in rats. Pharmacol Biochem Behav 73, 779-86 (2002b)
141. RR Matsumoto, WD Bowen, MA Tom, VN Vo, DD Truong, BR De Costa: Characterization of two novel sigma receptor ligands: Antidystonic effects in rats suggest sigma receptor antagonism. Eur J Pharmacol 280(3), 301-10 (1995)
142. KA McCracken, WD Bowen, BR De Costa, RR Matsumoto: Two novel sigma receptor ligands, BD1047 and LR172, attenuate cocaine-induced toxicity and locomotor activity. Eur J Pharmacol 370, 225-2 (1999)
143. SW Tam, GF Steinfels, PJ Gilligan, WK Schmidt, L Cook: DuP 734 [1-(cyclopropylmethyl)-4-(2(4-Flurophenyl)-2-oxoethyl)-piperidine HBr], a sigma and 5-Hydroxytryptamine2 receptor antagonist: Receptor-Binding, electrophysiological and neuropharmacological profiles. J Pharmacol Exp Ther 263, 1167-74 (1992)
144. R Mechoulam, P Braun, Y Gaoni: A stereospecific synthesis of (-)delta 1-And (-)delta 1(6)-Tetrahydrocannabinols. J Am Chem Soc 89, 4552-4 (1967)
145. R Mechoulam, JJ Feigenbaum, N Lander, M Segal, TU Järbe, AJ Hiltunen, P Consroe: Enantiomeric cannabinoids: Stereospecificity of psychotropic activity. Experientia 44(9) 762-4 (1988)
146. M Rinaldi-Carmona, B Calandra, D Shire, M Bouaboula, D Oustric, F Barth, P Casellas, P Ferrara, G Le Fur: Characterization of two cloned human CB1 cannabinoid receptor isoforms. J Pharmacol Exp Ther 278(2), 871-8 (1996)
147. M Rinaldi-Carmona, F Barth, J Millan, JM Derocq, P Casellas, C Congy, D Oustric, M Sarran, M Bouaboula, B Calandra: SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 284, 644-50 (1998)
148. DR Compton, LH Gold, SJ Ward, RL Balster, BR Martin: Aminoalkylindole analogs: Cannabimimetic activity of a class of compounds structurally distinct from delta 9-Tetrahydrocannabinol. J Pharmacol Exp Ther 263, 1118, 26 (1992)
149. DR Compton, M Aceto, J Lowe, BR Martin: In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A) : Inhibition of delta 9-Tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 277, 586-94 (1996)
150. ME Abood, BR Martin: Neurobiology of marijuana abuse. Trends Pharmacol Sci 13, 201-6 (1992)
151. LA Matsuda, TI Bonner, SJ Lolait: 2: Cannabinoid receptors: which cells, where, how, and why? NIDA Res Monogr 126, 48-56 (1992)
152. WA Devane, L Hanus, A Breuer, RG Pertwee, LA Stevenson, G Griffin, D Gibson, A Mandelbaum, A Etinger, R Mechoulam: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-49 (1992)
153. AC Howlett: Cannabinoid receptor signaling. Handb Exp Pharmacol 168, 53-79 (2005)
154. D Osei-Hyiaman, M DePetrillo, P Pacher, J Liu, S Radaeva, S Bátkai, J Harvey-White, K Mackie, L Offertáler, L Wang, G Kunos: Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115(5), 1298-305 (2005)
155. JC Ashton, M Glass: The Cannabinoid CB2 Receptor as a Target for Inflammation-Dependent Neurodegeneration. Curr Neuropharmacol 5, 73-80 (2007)
156. MD Van Sickle, M Duncan, PJ Kingsley, A Mouihate, P Urbani, K Mackie, N Stella, A Makriyannis, D Piomelli, JS Davison, LJ Marnett, V Di Marzo, QJ Pittman, KD Patel, KA Sharkey: Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310, 329-32 (2005)
157. A Brusco, PA Tagliaferro, T Saez, ES Onaivi: Ultrastructural localization of neuronal brain CB2 cannabinoid receptors. Ann N Y Acad Sci 1139, 450-457 (2008)
158. R Mechoulam, S Ben-Shabat, L Hanus, M Ligumsky, NE Kaminski, AR Schatz, A Gopher, S Almog, BR Martin, DR Compton: Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50, 83-90 (1995)
159. T Sugiura, K Waku: 2-Arachidonoylglycerol and the cannabinoid receptors. Chem Phys Lipids 108, 89-106 (2000)
160. L Hanus, S Abu-Lafi, E Fride, A Breuer, Z Vogel, De Shalev, I Kustanovich, R Mechoulam: 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 98, 3662-65 (2001)
161. T Bisogno, D Melck, MY Bobrov, NM Gretskaya, VV Bezuglov, L De Petrocellis, V Di Marzo: N-Acyl-Dopamines: Novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J 351, 817-824 (2000)
162. AS Heimann, I Gomes, CS Dale, RL Pagano, A Gupta, LL De Souza, AD Luchessi, LM Castro, R Giorgi, V Rioli, ES Ferro, LA Devi: Femopressin is an inverse agonist of CB1 cannabinoid receptors. Proc Natl Acad Sci USA 104, 20588-93 (2007)
163. BF Cravatt, DK Giang, SP Mayfield, DL Boger, RA Lerner, NB Gilula: Molecular characterization of an enzyme that degrades neuromodulatory fatty-Acid amides. Nature 384, 83-7 (1996)
164. M Karlsson, JA Contreras, U Hellman, H Tornqvist, C Holm: CDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases. J Biol Chem 272, 27218-23 (1997)
165. V Di Marzo: Biosynthesis and inactivation of endocannabinoids: Relevance to their proposed role as neuromodulators. Life Sci 65, 645-55 (2009)
166. DG Johns, DJ Behm, DJ Walker, Z Ao, EM Shapland, DA Daniels, M Riddick, S Dowell, PC Staton, P Green, U Shabon, W Bao, N Aiyar, TL Yue, AJ Brown, AD Morrison, SA Douglas. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol 152, 825-31 (2007)
167. E Ryberg, N Larsson, S Sjogren, S Hjorth, NO Hermansson, J Leonova, T Elebring, K Nilsson, T Drmota, PJ Greasley: The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152, 1092-101 (2007)
168. I Bab, A Zimmer: Cannabinoid receptors and the regulation of bone mass. Br J Pharmacol 153(2), 182-8 (2008)
169. PC Staton, JP Hatcher, DJ Walker, AD Morrison, EM Shapland, JP Hughes, E
170. M Sawzdargo, T Nguyen, DK Lee, KR Lynch, R Cheng, HH Heng, SR George, BF O?Dowd: Identification and cloning of three novel human G protein-Coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res 64, 193-8 (1999)
171. RG Pertwee: Tolerance to the effect of delta1-Tetrahydrocannabinol on corticosterone levels in mouse plasma produced by repeated administration of cannabis extract or delta1-Tetrahydrocannabinol. Br J Pharmacol 51, 391-7 (1974)
172. RG Pertwee, R Tavendale: Effects of delta9-Tetrahydrocannabinol on the rates of oxygen consumption of mice. Br J Pharmacol 60, 559-68 (1977)
173. MR Fennessy, DA Taylor: The effect of delta9-Tetrahydrocannabinol on body temperature and brain amine concentrations in the rat at different ambient temperatures. Br J Pharmacol 60, 65-71 (1997)
174. LF Englert, BT Ho, D Taylor: The effects of (-)delta9- Tetrahydrocannabinol on reserpine-induced hypothermia in rats. Br J Pharmacol 49, 243-52 (1973)
175. AG Fitton, RG Pertwee: Changes in body temperature and oxygen consumption rate of conscious mice produced by intrahypothalamic and intracerebroventricular injections of delta 9-Tetrahydrocannabinol. Br J Pharmacol 75, 409-414 (1982)
176. F Fan, DR Compton, SJ Ward, L Melvin, BR Martin: Development of cross-Tolerance between delta 9-Tetrahydrocannabinol, CP 55,940 and WIN 55,212. J Pharmacol Exp Ther 271, 1383-90 (1994)
177. E Spina, A Trovati, D Parolaro, G Giagnoni: A role of nitric oxide in WIN 55,212-2 tolerance in mice. Eur J Pharmacol 343, 157-63 (1998)
178. A Fox, A Kesingland, C Gentry, K McNair, S Patel, L Urban, I James: The role of central and peripheral cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 92, 91-100 (2001)
179. SM Rawls, J Cabassa, EB Geller, MW Adler: CB1 receptors in the preoptic anterior hypothalamus regulate WIN 55212-2[(4,5-Dihydro-2-methyl-4(4- morpholinylmethyl)-1-(1-naphthalenyl-Carbonyl)-6Hpyrrolo[ 3,2,1ij]quinolin-6- one]-induced hypothermia. J Pharmacol Exp Ther 301, 963-8 (2002a)
180. SM Rawls, RJ Tallarida, AM Gray, EB Geller, MW Adler: L-NAME (N omega-nitro-L-Arginine methyl ester), a nitric-oxide synthase inhibitor and WIN 55212-2 [4,5-Dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-Carbonyl) -6H pyrrolo[3,2,1ij]quinolin-6-one], a cannabinoid agonist, interact to evoke synergistic hypothermia. J Pharmacol Exp Ther 308, 780-6 (2004a)
181. SM Rawls, RJ Tallarida, DA Kon, EB Geller, MW Adler: GABAA receptors modulate cannabinoid-evoked hypothermia. Pharmacol Biochem Behav 78, 83-91 (2004b)
182. C Ledent, O Valverde, G Cossu, F Petitet, JF Aubert, F Beslot, GA Böhme, A Imperato, T Pedrazzini, BP Roques, et al: Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283, 401-4 (1999)
183. A Zimmer, AM Zimmer, AG Hohmann, M Herkenham, TI Bonner: Increased mortality, hypoactivity and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 96, 5780-85 (1999)
184. IS McGregor, CN Issakidis, G Prior: Aversive effects of the synthetic cannabinoid CP 55,940 in rats. Pharmacol Biochem Behav 53, 657-64 (1996)
185. F Nava, G Carta, GL Gessa: Permissive role of dopamine D(2) receptors in the hypothermia induced by delta(9)-Tetrahydrocannabinol in rats. Pharmacol Biochem Behav 66, 183-7 (2000)
186. JL Wiley, RL Barrett, J Lowe, RL Balster, BR Martin: Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats. Neuropharmacology 34, 669-76 (1995)
187. SM Rawls, A Cowan, RJ Tallarida, EB Geller, MW Adler: N-methyl-D-Aspartate antagonists and WIN 55212-2 [4,5-Dihydro-2-methyl-4(4- morpholinylmethyl)-1-(1-naphthalenyl-Carbonyl)-6H-pyrrolo[3,2,1i,j] quinolin-6-one], a cannabinoid agonist, interact to produce synergistic hypothermia. J Pharmacol Exp Ther 303, 395-402 (2002c)
188. H Ovadia, A Wohlman, R Mechoulam, J Weidenfeld: Characterization of the hypothermic effect of the synthetic cannabinoid HU-210 in the rat. Relation to the adrenergic system and endogenous pyrogens. Neuropharmacology 34, 175-80 (1995)
189. M Herkenham, AB Lynn, MR Johnson, LS Melvin, BR De Costa, KC Rice: Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J Neurosci 11, 563-583 (1991)
190. P Mailleux, JJ Vanderhaeghen: Distribution of neuronal cannabinoid receptor in the adult rat brain: A comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 48, 655-68 (1992)
191. G Moldrich, T Wenger: Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study. Peptides 21, 1735-42 (2000)
192. DA Pettit, MP Harrison, JM Olson, RF Spencer, GA Cabral: Immunohistochemical localization of the neural cannabinoid receptor in rat brain. J Neurosci Res 51, 391-402 (1998)
193. K Tsou, S Brown, MC Sanudo-Pena, K Mackie, JM Walker: Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83, 393-411 (1998)
194. F Chaperon, MH Thiebot: Behavioral effects of cannabinoid agents in animal. Crit Rev Neurobiol 13, 243-81 (1990)
195. WT Schmeling, MJ Hosko: Fypothermic effects of intraventricular and intravenous administration of cannabinoids in intact and brainstem transected cats. Neuropharmacology 19, 567-73 (1980)
196. NR Gavva: Body-Temperature maintenance as the predominant function of the vanilloid receptor TRPV1. Trends Pharmacol Sci 29 (11), 550-7 (2008)
197. NR Gavva, AW Bannon, S Surapaneni, DN Hovland Jr, SG Lehto, A Gore, T Juan, H Deng, B Han, L Klionsky, R Kuang, A Le, R Tamir, J Wang, B Youngblood, D Zhu, MH Norman, E Magal, JJ Treanor, JC Louis: The vanilloid receptor TRPV1 is tonically activated in vivo and involved in body temperature regulation. J Neurosci 27, 3366-74 (2007)
198. A Calignano, G La Rana, A Giuffrida, D Piomelli: Control of pain initiation by endogenous cannabinoids. Nature 394, 277-81 (1998)
199. SP Welch, JW Huffman, J Lowe: Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. J Pharmacol Exp Ther 286, 1301-8 (1998)
200. J Hodge, JP Bow, KS Plyler, VK Vemuri, A Wisniecki, JD Salamone, A Makriyannis, PJ McLaughlin: The cannabinoid CB1 receptor inverse agonist AM 251 and antagonist AM 4113 produce similar effects on the behavioral satiety sequence in rats. Behav Brain Res 193, 298-305 (2008)
201. KS Sink, VK. Vemuri, J Wood, A Makriyannis, JD Salamone: Oral bioavailability of the novel cannabinoid CB1 antagonist AM6527: Effects on food-reinforced behavior and comparisons with AM4113. Pharmacol Biochem Behav 91, 303-306 (2009)
202. V Di Marzo: The endocannabinoid system: Its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation: Pharmacol Res 60, 77-84 (2009)
203. TP Dinh, D Carpenter, FM Leslie, TF Freund, I Katona, SL Sensi, S Kathuria, D Piomelli: Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 99, 10819-24 (2002)
204. TF Freund, I Katona, D Piomelli: Role of endogenous cannabinoids in synaptic signaling. Physiol Rev, 83, 1017-1066(2003)
205. M Beltramo, N Stella, A Calignano, SY Lin, A Makriyannis, D Piomelli: Functional role of high-Affinity anandamide transport, as revealed by selective inhibition. Science 277, 1094-1097(1997)
206. M Beltramo, FR De Fonseca, M Navarro, A Calignano, MA Gorriti, AG Grammatikopoulos, G Sadile, A Giuffrida, D Piomelli: Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor: J Neurosci 20, 3401-3407(2000)
207. A Calignano, G La Rana, M Beltramo, A Makriyannis, D Piomelli: Potentiation of anandamide hypotension by the transport inhibitor, AM404. Eur. J Pharmacol 15, 337, R1-2(1997)
208. PM Zygmunt, HH Chuang, P Movahed, DJulius, ED Högestätt: The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur J Pharmacol 396, 39-42 (2000)
209. BG Kelley, SA Thayer: Anandamide transport inhibitor AM 404 and structurally related compounds inhibit synaptic transmission between rat hippocampal neurons in culture independent of cannabinoid CB1 receptors. Eur J Pharmacol 496, 33-39 (2004)
210. RA Nicholson, C Liao, J Zheng, LS David, L Coyne, AC Errington, et al.: Sodium channel inhibition by anandamide and synthetic cannabimimetics in brain. Brain Res 978, 194-204 (2003)
211. N Hajos, S Kathuria, T Dinh, D Piomelli, TF Freund: Endocannabinoid transport tightly controls 2-Arachidonoyl glycerol actions in the hippocampus: Effects of low temperature and the transport inhibitor AM404. Eur J Neurosci 19, 2991-2996 (2004)
212. WC Chen, JK Huang, JS Cheng, JCR Tsai, AJ Chiang, KJ Chou, et al.: AM-404 elevates renal intracellular Ca2+, questioning its selectivity as a pharmacological tool for investigating the anandamide transporter. J Pharmacol Toxicol Methods 45, 195-198 (2001)
213. KO Jonsson, A Andersson, SO Jacobsson, S Vandevoorde, DM Lambert, CJ Fowler: AM 404 and VDM 11 non-specifically inhibit C6 glioma cell proliferation at concentrations used to block the cellular accumulation of the endocannabinoid anandamide. Arch Toxicol 77, 201-207 (2003)
214. M Van der Stelt, V Di Marzo: The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: Implications for neurological and psychiatric disorders. Eur J Pharmacol 480, 133-150 (2003)
215. SM Rawls, Z Ding, A Cowan: Role of TRPV1 and cannabinoid CB1 receptors in AM 404-evoked hypothermia in rats. Pharmacol Biochem Behav 83,508-516 (2006c)
216. L De Petrocellis, T Bisogno, JB Davis, RG Pertwe, V Di Marzo: Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: Inhibitors of anandamide uptake with negligible capsaicin-like activity: FEBS Lett 483, 52-56 (2000)
217. RA Ross, TM Gibson, HC Brockie, M Leslie, G Pashmi, SJ Craib, et al: Structure-Activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br J Pharmacol 13, 631-640 (2001)
218. MS Miller, K Brendel, SH Buck, TF Burks: Dihydrocapsaicin-induced hypothermia and substance P depletion. Eur J Pharmacol 83, 289-292 (1982)
219. AG Hayes, A Oxford, M Reynolds, AH Shingler, M Skingle, C Smith, MB Tyers: The effects of a series of capsaicin analogues on nociception and body temperature in the rat. Life Sci 34, 1241-1248 (1984)
220. Z Ding, A Cowan, SM Rawls: Capsaicin evokes hypothermia independent of cannabinoid CB1 and CB2 receptors. Brain Res 1065, 147-151 (2005)
221. MD Dogan, S Patel, AY Rudaya, AA Steiner, M Székely, AA Romanovsky: Lipopolysaccharide fever is initiated via a capsaicin-sensitive mechanism independent of the subtype-1 vanilloid receptor. Br J Pharmacol 143, 1023-1032 (2004)
222. A Varga, J Németh, A Szabó, J McDougall, C Zhang, K Elekes, E Pintér, J Szolcsányi, Z Helyes: Effects of the novel TRPV1 receptor antagonist SB366791 in vitro and in vivo in the rat. Neurosci Lett 385, 137-142 (2005)
223. L De Petrocellis, T Bisogno, M Maccarrone, JB Davis, A Finazzi-Agro, V Di Marzo: The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J Biol Chem 276, 12856-12863 (2001)
224. GY Wong, NR Gavva: Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks. Brain Res Rev 60, 267-277 (2009)
225. LS Premkumar, GP Ahern: Induction of vanilloid receptor channel activity by protein kinase C. Nature 408, 985-990 (2000)
226. Z Ding, T Gomez, JL Werkheiser, A Cowan, SM Rawls: Icilin induces a hyperthermia in rats that is dependent on nitric oxide production and NMDA receptor activation. Eur J Pharmacol 578, 201-208 (2008)
227. MJ Caterina: Transient receptor potential ion channels as participants in thermosensation and thermoregulation. Am J Physiol Regul Integr Comp Physiol 292, 64-76 (2007)
228. DN Ruskin, R Anand, GJ Lahoste: Menthol and nicotine oppositely modulate body temperature in the rat. Eur J Pharmacol 559, 161-164 (2007)
229. DD McKemy, WM Neuhausser, D Julius: Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature 416, 52-58 (2002)
230. AM Peier, A Moqrich, AC Hergarden, AJ Reeve, DA Andersson, GM Story, TJ Earley, I Dragoni, P McIntyre, S Bevan, A Patapoutian: A TRP channel that senses cold stimuli and menthol. Cell 108, 705-715 (2002)
231. GM Story, AM Peier, AJ Reeve, SR Eid, J Mosbacher, TR Hricik, TJ Earley, AC Hergarden, DA Andersson, SW Hwang, P McIntyre, T Jegla, S Bevan, A Patapoutian: ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell 112, 819-829 (2003)
232. M Bandell, GM Story, SW Hwang, V Viswanath, SR Eid, MJ Petrus, TJ Earley, A Patapoutian: Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron 41, 849-857 (2004)
233. ET Wei, DA Seid: AG-3-5: A chemical producing sensations of cold. J Pharm Pharmacol 35, 110-112 (1983)
234. G Reid, A Babes, F Pluteanu: A cold and mentholactivated current in rat dorsal root ganglion neurons, properties and role in cold transduction. J Physiol 545, 596-614 (2002)
235. G Reid, ML Flonta: Ion channels activated by cold and menthol in cultured rat dorsal root ganglion neurons. Neurosci Lett, 324, 164-168 (2002)
236. ML Nealen, MS Gold, PD Thut, MJ Caterina: TRPM8 mRNA is expressed in a subset of cold-responsive trigeminal neurons from rat. J Neurophysiol 90, 515-520 (2003)
237. PD Thut, D Wrigley, MS Gold: Cold transduction in rat trigeminal ganglia neurons in vitro. Neuroscience 119, 1071-1083 (2003)
238. A Dhaka, AN Murray, J Mathur, TJ Earley, MJ Petrus, A Patapoutian: TRPM8 is required for cold sensation in mice. Neuron 54, 371-378 (2007)
239. ET Wei: Chemical stimulants of shaking behavior. J Pharm Pharmacol 28, 722-723 (1976)
240. JL Werkheiser, SM Rawls, A Cowan: Mu and kappa opioid receptor agonists antagonize icilin-induced wet-Dog shaking in rats. Eur J Pharmacol 547, 101-105 (2006) Opioids, cannabinoids, and thermoregulation 844
241. JL Werkheiser, SM Rawls, A Cowan: Nalfurafine, the kappa opioid agonist, inhibits icilin-induced wet-Dog shakes in rats and antagonizes glutamate release in the dorsal striatum. Neuropharmacology 52, 925-930 (2007)
242. K. Benamar, M Yondorf, EB Geller, TK Eisenstein, MW Adler: Physiological evidence for interaction between the HIV-1 co-receptor CXCR4 and the cannabinoid system in the brain. Br J Pharmacol 157, 1225-1231 (2009)
243. DT Malone, DA Taylor: Modulation of delta9-Tetrahydrocannabinol-induced hypothermia by fluoxetine in the rat. Br J Pharmacol 124, 1419-1424 (1998)
244. DT Malone, DA Taylor: Involvement of somatodendritic 5-HT(1A) receptors in Delta(9)-Tetrahydrocannabinol-induced hypothermia in the rat. Pharmacol Biochem Behav 69, 595-601 (2001)
245. H Kinoshita, T Hasegawa, T Kameyama, I Yamamoto, T Nabeshima: Competitive NMDA antagonists enhance the catalepsy induced by delta 9-Tetrahydrocannabinol in mice. Neurosci Lett 174, 101-104 (1994)
246. S Kelly, V Chapman: Selective cannabinoid CB1 receptor activation inhibits spinal nociceptive transmission in vivo. J Neurophysiol 86, 3061-3064 (2001)
247. E Palazzo, I Marabese, V De Novellis, P Oliva, F Rossi, L Berrino, F Rossi, S Maione: Metabotropic and NMDA glutamate receptors participate in the cannabinoidinduced antinociception. Neuropharmacology 40, 319-326 (2001)
248. K Yakimova, R Ovtcharov: Central temperature effects of the transmitter amino acids. Acta Physiol Pharmacol Bulg 15, 50-55 (1989)
249. J Singh, MC Gupta: Effect of aspartate and glutamate on nociception, catalepsy and core temperature in rats. Indian J Physiol Pharmacol 41, 123-128 (1997)
250. WT Huang, SM Tsai, MT Lin: Involvement of brain glutamate release in pyrogenic fever. Neuropharmacology 41, 811-818 (2001)
251. D Corbett, S Evans, C Thomas, D Wang, RA Jonas: MK-801 reduced cerebral ischemic injury by inducing hypothermia. Brain Res 514, 300-304 (1990)
252. GM Farfel, LS Seiden: Role of hypothermia in the mechanism of protection against serotonergic toxicity. II. Experiments with methamphetamine, pchloroamphetamine, fenfluramine, dizocilpine and dextromethorphan. J Pharmacol Exp Ther 272, 868-875 (1995)
253. N Hajos, C Ledent, TF Freund: Novel cannabinoidsensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106, 1-4 (2001)
254. M Shen, TM Piser, VS Seybold, SA Thayer: Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 16, 4322-4334 (1996)
255. AC Howlett: Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds. Life Sci 35, 1803-1810 (1984)
256. K Mackie, B Hille: Cannabinoids inhibit N-Type calcium channels in neuroblastoma-Glioma cells. Proc Natl Acad Sci USA 89, 3825-3829 (1992)
257. RJ Tallarida: Drug synergism: Its detection and applications. J Pharmacol Exp Ther 298, 865-872 (2001)
258. AC Howlett: Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol 35, 607-634 (1995)
259. SC Azad, G Marsicano, I Eberlein, J Putzke, W Zieglgansberger, R Spanagel, B Lutz: Differential role of the NO pathway on delta(9)-THC-induced central nervous system effects in the mouse. Eur J Neurosci 13, 561-568 (2001)
260. DG Deutsch, MS Goligorsky, PC Schmid, RJ Krebsbach, HH Schmid, SK Das, SK Dey, G Arreaza, C Thorup, G Stefano, et al.: Production and physiological actions of anandamide in the vasculature of the rat kidney. J C Investig 100, 1538-1546 (1997)
261. GB Stefano, TV Bilfinger, CM Rialas, DG Deutsch: 2-Arachidonyl-Glycerol stimulates nitric oxide release from human immune and vascular tissues and invertebrate immunocytes by cannabinoid receptor 1. Pharmacol Res 42, 317-322 (2000)
262. GB Stefano, B Salzet, CM Rialas, M Pope, A Kustka, K Neenan, S Pryor, M Salzet: Morphine-And anandamidestimulated nitric oxide production inhibits presynaptic dopamine release. Brain Res 763, 63-68 (1997)
263. J Roth, B Storr, K Voigt, E Zeisberger: Inhibition of nitric oxide synthase attenuates lipopolysaccharide-induced fever without reduction of circulating cytokines in guineapigs. Pflueg Arch 436, 858-862 (1998)
264. K Benamar, L Xin, EB Geller, MW Adler: Effect of central and peripheral administration of a nitric-oxide synthase inhibitor on morphine hyperthermia in rats: Brain Res 894, 266-273 (2001)
265. VE Mendizabal, ML Orliac, E Adler-Graschinsky: Long-Term inhibition of nitric oxide synthase potentiates effects of anandamide in the rat mesenteric bed. Eur J Pharmacol 427, 251-262 (2001)
266. CJ Hillard, S Muthian, CS Kearn; Effects of CB(1) cannabinoid receptor activation on cerebellar granule cell nitric oxide synthase activity. FEBS Lett 459, 277-281 (1999)
267. M Chebib, GA Johnston: The ?ABC? of GABA receptors: A brief review. Clin Exp Pharmacol Physiol 26, 937-940 (1999)
268. MR Zarrindast, Y Oveissi: GABAA and GABAB receptor sites involvement in rat thermoregulation. Gen Pharmacol 19, 223-226 (1988)
269. M Sancibrian, JS Serrano, FJ Minano: Opioid and prostaglandin mechanisms involved in the effects of GABAergic drugs on body temperature. Gen Pharmacol 22, 259-262 (1991)
270. BD Phillis, J Ong, JM White, C Bonnielle: Modification of amphetamine-induced responses by baclofen in rats. Psychopharmacology 153, 277-284 (2001)
271. SK Jha, F Islam, BN Mallick: GABA exerts opposite influence on warm and cold sensitive neurons in medial preoptic area in rats. J Neurobiol 48, 291-300 (2001)
272. SK Jha, V Yadav, BN Mallick: GABA-A receptors in mPOAH simultaneously regulate sleep and body temperature in freely moving rats. Pharmacol Biochem Behav 70, 115-121 (2001)
273. H Okamura, M Abitbol, JF Julien, S Dumas, A Berod, M Geffard, et al.: Neurons containing messenger RNA encoding glutamate decarboxylase in rat hypothalamus demonstrated by in situ hybridization, with special emphasis on cell groups in medial preoptic area, anterior hypothalamic area and dorsomedial hypothalamic nucleus. Neuroscience 39, 675-699 (1990)
274. RG Pertwee, SE Browne, TM Ross, CD Stretton: An investigation of the involvement of GABA in certain pharmacological effects of delta-9- Tetrahydrocannabinol. Pharmacol Biochem Behav 40, 581-585 (1991)
275. RG Pertwee, SG Greentree: Delta-9-Tetrahydrocannabinol-induced catalepsy in mice is enhanced by pretreatment with flurazepam or chlordiazepoxide. Neuropharmacology 27, 485-491 (1988)
276. RG Pertwee, SG Greentree, PA Swift: Drugs which stimulate or facilitate central GABAergic transmission interact synergistically with delta-9-Tetrahydrocannabinol to produce marked catalepsy in mice. Neuropharmacology 27, 1265-1270 (1988b)
277. SM Rawls, RJ Tallarida, J Zisk: Agmatine and a cannabinoid agonist, WIN 55212-2, interact to produce a hypothermic synergy. Eur J Pharmacol 553, 89-98 (2006)
278. S Aggarwal, B Shavalian, E Kim, SM Rawls: Agmatine enhances cannabinoid action in the hot-plate assay of thermal nociception: Pharmacol Biochem Behav 93, 426-432 (2009)
279. K Benamar, M Yondorf, JJ Meissler, EB Geller, RJ Tallarida, TK Eisenstein, MW Adler: A novel role of cannabinoids: Implication in the fever induced by bacterial lipopolysaccharide. J Pharmacol Exp Ther 320, 1127-1133 (2007)
280. MJ Kluger, W Kozak, LR Leon, D Soszynski, CA Conn: 3.Cytokines and fever. Neuroimmunomodulation 2, 216-223 (1995)
281. TW Klein, C Newton, H Friedman: Cannabinoid receptors and immunity. Immunol Today 19, 373-381 (1998)
282. Y Feng, CC Broder, PE Kennedy, EA Berger: FIV-1 entry cofactor: Functional cDNA cloning of a seventransmembrane, G protein-Coupled receptor. Science 272, 872-877 (1996)
283. G Banisadr, D Skrzydelski, P Kitabgi, W Rostène, SM Parsadaniantz: Fighly regionalized distribution of stromal cell-Derived factor-1/CXCL12 in adult rat brain: Constitutive expression in cholinergic, dopaminergic and vasopressinergic neurons. Eur J Neurosci 18, 1593-1606 (2003)
284. G Corley, SM Rawls: Opioid, cannabinoid CB1 and NOP receptors do not mediate APAP-induced hypothermia in rats. Pharmacol Biochem Behav 92, 503-507 (2008)
285. LA Pini, G Vitale, A Ottani, M Sandrini: Naloxonereversible antinociception by paracetamolin the rat. J Pharmacol Exp Ther 280, 934-940 (1997)
286. M Bujalska: Effect of nonselective and selective opioid receptors antagonists on antinociceptive action of APAP [part III]. Pol J Pharmacol 56, 539-545 (2004)
287. A Ottani, S Leone, M Sandrini, A Ferrari, A Bertolini: The analgesic activity of paracetamol isprevented by the blockade of cannabinoid CB1 receptors. Eur J Pharmacol 531, 280-281 (2006)
288. RR Leker, N Gai, R Mechoulam, H Ovadia: Drug-Induced Hypothermia Reduces Ischemic Damage: Effects of the Cannabinoid HU-210. Stroke 34, 2000-2006 (2003)
289. W Sieghart, K Fuchs, J Zezula, A Buchstaller, F Zimprich, H Lassmann: Biochemical,immunological,and pharmacological characterization of GABAAbenzodiazepine receptor subtypes. Adv Biochem Psychopharmacol 47, 155-162 (1992)